Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.18 Billion EUR | -11.27% |
| 2022 | 1.34 Billion USD | 13.54% |
| 2021 | 1.18 Billion EUR | -10.92% |
| 2020 | 1.32 Billion EUR | 12.53% |
| 2019 | 1.17 Billion EUR | 20.41% |
| 2018 | 978.3 Million EUR | -5.35% |
| 2017 | 1.03 Billion EUR | -3.72% |
| 2016 | 1.07 Billion EUR | -2.58% |
| 2015 | 1.1 Billion EUR | 8.53% |
| 2014 | 1.01 Billion EUR | 0.83% |
| 2013 | 1 Billion EUR | 2.71% |
| 2012 | 980.3 Million EUR | 6.8% |
| 2011 | 917.9 Million EUR | 8.0% |
| 2010 | 849.9 Million EUR | 10.16% |
| 2009 | 771.5 Million EUR | 8.55% |
| 2008 | 710.7 Million EUR | 4.51% |
| 2007 | 680 Million EUR | 118.51% |
| 2006 | 311.2 Million EUR | -83.64% |
| 2005 | 1.9 Billion EUR | -2.28% |
| 2004 | 1.94 Billion EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 333.08 Million EUR | -3.86% |
| 2024 Q2 | 328.3 Million EUR | 6.12% |
| 2024 Q3 | 471.3 Million EUR | 43.86% |
| 2023 Q1 | 303.46 Million USD | -3.72% |
| 2023 FY | 1.18 Billion EUR | -11.27% |
| 2023 Q4 | 354.41 Million EUR | 11.27% |
| 2023 Q3 | 318.5 Million USD | 1.0% |
| 2023 Q2 | 315.33 Million USD | 3.91% |
| 2022 Q3 | 481.97 Million EUR | 62.11% |
| 2022 FY | 1.34 Billion USD | 13.54% |
| 2022 Q2 | 297.31 Million EUR | 9.87% |
| 2022 Q4 | 315.18 Million USD | -34.61% |
| 2022 Q1 | 270.6 Million EUR | -2.13% |
| 2021 Q4 | 276.5 Million EUR | 14.78% |
| 2021 Q1 | 315.8 Million EUR | 23.65% |
| 2021 Q2 | 302.28 Million EUR | -4.28% |
| 2021 Q3 | 240.9 Million EUR | -20.31% |
| 2021 FY | 1.18 Billion EUR | -10.92% |
| 2020 Q3 | 250.4 Million EUR | -14.42% |
| 2020 Q1 | 279.9 Million EUR | 1.97% |
| 2020 Q2 | 292.6 Million EUR | 4.54% |
| 2020 FY | 1.32 Billion EUR | 12.53% |
| 2020 Q4 | 255.4 Million EUR | 2.0% |
| 2019 Q2 | 251.7 Million EUR | 4.44% |
| 2019 Q1 | 241 Million EUR | -8.16% |
| 2019 FY | 1.17 Billion EUR | 20.41% |
| 2019 Q4 | 274.5 Million EUR | -3.24% |
| 2019 Q3 | 283.7 Million EUR | 12.71% |
| 2018 FY | 978.3 Million EUR | -5.35% |
| 2018 Q4 | 262.4 Million EUR | 18.3% |
| 2018 Q3 | 221.8 Million EUR | -9.87% |
| 2018 Q2 | 246.1 Million EUR | -0.4% |
| 2018 Q1 | 247.1 Million EUR | -11.88% |
| 2017 Q4 | 280.4 Million EUR | 16.11% |
| 2017 Q3 | 241.5 Million EUR | -7.36% |
| 2017 Q2 | 260.7 Million EUR | -1.81% |
| 2017 Q1 | 265.5 Million EUR | -5.14% |
| 2017 FY | 1.03 Billion EUR | -3.72% |
| 2016 Q3 | 258.6 Million EUR | -5.31% |
| 2016 Q4 | 279.9 Million EUR | 8.24% |
| 2016 Q1 | 262 Million EUR | 0.15% |
| 2016 Q2 | 273.1 Million EUR | 4.24% |
| 2016 FY | 1.07 Billion EUR | -2.58% |
| 2015 Q3 | 239.1 Million EUR | -6.24% |
| 2015 FY | 1.1 Billion EUR | 8.53% |
| 2015 Q4 | 261.6 Million EUR | 9.41% |
| 2015 Q2 | 255 Million EUR | -1.89% |
| 2015 Q1 | 259.9 Million EUR | 1.8% |
| 2014 Q3 | 238.4 Million EUR | -13.81% |
| 2014 Q1 | 245 Million EUR | -10.12% |
| 2014 Q4 | 255.3 Million EUR | 7.09% |
| 2014 FY | 1.01 Billion EUR | 0.83% |
| 2014 Q2 | 276.6 Million EUR | 12.9% |
| 2013 Q1 | 249.3 Million EUR | -1.97% |
| 2013 FY | 1 Billion EUR | 2.71% |
| 2013 Q2 | 248.1 Million EUR | -0.48% |
| 2013 Q4 | 272.6 Million EUR | 15.07% |
| 2013 Q3 | 236.9 Million EUR | -4.51% |
| 2012 FY | 980.3 Million EUR | 6.8% |
| 2012 Q1 | 247.4 Million EUR | 4.79% |
| 2012 Q4 | 254.3 Million EUR | 3.46% |
| 2012 Q3 | 245.8 Million EUR | 5.58% |
| 2012 Q2 | 232.8 Million EUR | -5.9% |
| 2011 Q1 | 244.1 Million EUR | 13.59% |
| 2011 Q3 | 210.7 Million EUR | -7.18% |
| 2011 Q4 | 236.1 Million EUR | 12.06% |
| 2011 FY | 917.9 Million EUR | 8.0% |
| 2011 Q2 | 227 Million EUR | -7.01% |
| 2010 Q3 | 213.2 Million EUR | 2.8% |
| 2010 Q4 | 214.9 Million EUR | 0.8% |
| 2010 Q1 | 214.5 Million EUR | 10.97% |
| 2010 FY | 849.9 Million EUR | 10.16% |
| 2010 Q2 | 207.4 Million EUR | -3.31% |
| 2009 Q2 | 196.4 Million EUR | 3.31% |
| 2009 FY | 771.5 Million EUR | 8.55% |
| 2009 Q4 | 193.3 Million EUR | 0.78% |
| 2009 Q3 | 191.8 Million EUR | -2.34% |
| 2009 Q1 | 190.1 Million EUR | 0.0% |
| 2008 FY | 710.7 Million EUR | 4.51% |
| 2007 FY | 680 Million EUR | 118.51% |
| 2006 FY | 311.2 Million EUR | -83.64% |
| 2005 FY | 1.9 Billion EUR | -2.28% |
| 2004 FY | 1.94 Billion EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | 97.464% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 97.357% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 96.217% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -8424.038% |
| Novartis AG | 46.66 Billion USD | 97.45% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | 39.89% |